Navigation Links
OrthoAccel® Technologies, Inc. Announces Definitive Distribution Agreement in Italy
Date:11/21/2011

HOUSTON, Nov. 21, 2011 /PRNewswire/ -- OrthoAccel® Technologies, Inc. announced this week that it has finalized a distribution agreement with Micerium S.p.A. based in Avegno for exclusive distribution rights of the AcceleDent™ System in Italy.

The AcceleDent™ System is currently being sold outside the USA and was first introduced in the United Kingdom in October 2009.  The lightweight appliance, used to speed up the rate of orthodontic treatment, is intended for 20 minutes of daily use.  Patients simply bite down on the Mouthpiece to hold it in place, which allows freedom of the hands to engage in other routine, daily activities during the treatment session.  Patients have reported using the appliance while engaged in a variety of activities, including homework, watching television, reading and listening to music.

Mike Kaufman, Vice President of Marketing and Business Development for OrthoAccel® commented, "Micerium is the most recent addition to our growing network of European distributors.  Italy is a key international market for us and it bodes well that this market leader shares our philosophy and excitement for how AcceleDent™ can change orthodontic treatment."  AcceleDent™ was introduced to the Italian orthodontic community during the SIDO meeting in Rome November 11-13.  Dr. Ravindra Nanda reported on the recent results from a randomized, controlled clinical trial conducted at the University of Texas Health Science Center at San Antonio under the guidance of Dr. Dubravko Pavlin where AcceleDent™ demonstrated, with statistical significance, that tooth movement could be safely accelerated by 38% to 50% during space closure and even more so during the alignment phase.

This definitive distribution agreement between OrthoAccel® and Micerium formalizes the intent to partner together that was initiated under a Terms of Agreement in June of this year.  Ottaviano Miceli, CEO of Micerium, expressed his enthusiasm, "I am excited about this new project. Our company has always paid attention to market innovations and we believe that AcceleDent is great news - a simple product that will bring many benefits to the orthodontic treatment in terms of time savings and results. In a short time we have already seen a great interest and desire to discover and try AcceleDent by the Italian orthodontists who want to offer the best treatment to their patients. " 

OrthoAccel® has been selling the AcceleDent™ System outside the USA since October 2009.  FDA clearance is pending based on an application submitted earlier this year.

About OrthoAccel® Technologies, Inc.
Based in Houston, Texas, OrthoAccel® Technologies, Inc. is a privately owned medical device company currently engaged in the development, manufacturing, and marketing of products to enhance dental care and orthodontic treatment.

About the
AcceleDent™ System
AcceleDent™
represents the first clinical approach to safely accelerate orthodontic tooth movement via modulating bone biology. The device has been studied clinically and applies gentle pulsing forces in combination with standard orthodontics to move teeth faster through accelerated bone remodeling. Importantly, the device works complementary with all existing orthodontic technologies. AcceleDent™ is neither FDA cleared nor FDA approved; it is currently investigational only in the United States. More information can be found at www.acceledent.com and www.acceledent.co.uk or requested via info@orthoaccel.com


'/>"/>
SOURCE OrthoAccel Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
2. Microchip Biotechnologies, Inc. Awarded Contract Under US Army Commercialization Pilot Program
3. JD Technologies, LLC Selected by FCT Ingenieurkeramik GmbH to Represent Their High Performance Ceramic Expertise In the United States
4. Neurobiological Technologies, Inc. (Nasdaq: NTII) Q4/08 Review Issued by Scimitar Equity, LLC
5. Palatin Technologies, Inc. Revised Call-In Number for Teleconference and Webcast to be held on September 30, 2008
6. Arbios Sells HepatAssist Bioartificial Liver System to HepaLife Technologies, Inc.
7. Advanced Analytical Technologies, Inc. Expands Into New Office and Production Space
8. AVAX Technologies, Inc. Announces Closing of Bridge Loan Financing
9. VNUS Medical Technologies, Inc. Announces the Hiring of Guido Smeets, MD, as Vice President of Clinical Research and Chief Medical Officer
10. Neurobiological Technologies, Inc. Reports First Quarter Fiscal Year 2009 Financial Results
11. GlaxoSmithKline Commences Tender Offer to Acquire Genelabs Technologies, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... , June 27, 2016  Liquid Biotech ... the funding of a Sponsored Research Agreement with ... tumor cells (CTCs) from cancer patients.  The funding ... CTC levels correlate with clinical outcomes in cancer ... data will then be employed to support the ...
(Date:6/24/2016)... June 24, 2016 Epic Sciences unveiled ... cancers susceptible to PARP inhibitors by targeting homologous ... (CTCs). The new test has already been incorporated ... multiple cancer types. Over 230 clinical ... response pathways, including PARP, ATM, ATR, DNA-PK and ...
(Date:6/23/2016)... ... 23, 2016 , ... Mosio, a leader in clinical research ... Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, Mosio revisits the ... tools, and strategies for clinical researchers. , “The landscape of how patients receive ...
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
Breaking Biology Technology:
(Date:5/12/2016)... 2016 WearablesResearch.com , a brand of ... results from the Q1 wave of its quarterly wearables ... consumers, receptivity to a program where they would receive ... insurance company. "We were surprised to see ... Michael LaColla , CEO of Troubadour Research, "primarily because ...
(Date:4/28/2016)... GOTHENBURG, Sweden , April 28, 2016 ... 1,491.2 M (139.9), up 966% compared with the first quarter of ... Operating profit totaled SEK 589.1 M (loss: 18.8) and the operating ... SEK 7.12 (loss: 0.32) Cash flow from operations was ... , The 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. ...
(Date:4/15/2016)... CHICAGO , April 15, 2016  A ... companies make more accurate underwriting decisions in a ... offering timely, competitively priced and high-value life insurance ... health screenings. With Force Diagnostics, rapid ... and lifestyle data readings (blood pressure, weight, pulse, ...
Breaking Biology News(10 mins):